

LISTING OF CLAIMS:

This listing of claims provided below will replace all prior versions and listings of claims in the application.

Please amend the claims as follows:

1-21. (Canceled).

22. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of unitary doses of viral particles of recombinant adenoviral vectors, wherein the adenoviral vectors comprise an adenoviral genome replaced with a therapeutic gene or DNA sequence regulated by a ubiquitous promoter, a tissue-specific promoter, or a combination thereof, that encodes for one or more therapeutic proteins for the treatment of fibrotic disorders in organs and a pharmaceutically compatible carrier, wherein the therapeutic proteins for the treatment of fibrotic disorders the latent and/or active protein MMP-8, MMP-1, MMP-2, MMP-9 and MMP-13; uPA wild type and/or modified; the truncated receptor for TGF-.beta. type II; betaglycan; HGF and Smad 7.

23. (Previously Presented) The pharmaceutical composition of claim 22, wherein the unitary dose is about 10^7 - 10^{14} viral particles.

24. (Previously Presented) A method of treating fibrotic disorders in a patient, comprising:
preparing a recombinant adenoviral vector containing a therapeutic gene or DNA sequence;
delivering the recombinant adenoviral vector by an administrative route to an organ; and
generating therapeutic proteins in the organ from the recombinant adenoviral vector to treat the fibrotic disorders.

25. (Currently Amended) The method of claim 24, wherein the administrative route is ~~endovenous~~ intravenous.
26. (Previously Presented) The method of claim 24, wherein the organ is selected from liver, lung, heart, kidney, skin, hypertrophic scars, and combinations thereof.
27. (Previously Presented) The method of claim 24, wherein the fibrotic disorders are hepatic fibrosis, pulmonary fibrosis, renal fibrosis, heart fibrosis, keloids, hypertrophic scars, or combinations thereof.

Please add the following new claims:

- 28. (New) The pharmaceutical composition according to claim 22, wherein the administration route is intravenous.
29. (New) The pharmaceutical composition according to claim 22, wherein the organs with fibrosis are liver, lung, heart, kidney, skin, and hypertrophic scars.
30. (New) The pharmaceutical composition according to claim 29, wherein the liver is cirrhotic liver.
31. (New) The pharmaceutical composition according to claim 22, wherein the composition is useful in the treatment of the hepatic fibrosis, pulmonary fibrosis, renal fibrosis, heart fibrosis, keloids and hypertrophic scars.
32. (New) The pharmaceutical composition according to claim 22, which does not induce lethal toxicity.--